Alnylam's slump deepens; Q2 earnings roundup; and more
Welcome to another edition of Endpoints Weekly, and happy August! The summer is speeding right along, and we’ve got the latest from biopharma’s earnings-palooza this week. Let’s dive into the news. Alnylam’s struggles became the ...
We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.